News headlines about Co-Diagnostics (NASDAQ:CODX) have trended somewhat negative this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Co-Diagnostics earned a news sentiment score of -0.01 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 47.0512008706501 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Co-Diagnostics (NASDAQ CODX) traded down $0.19 during trading on Tuesday, hitting $4.95. 31,800 shares of the stock traded hands, compared to its average volume of 77,227. Co-Diagnostics has a fifty-two week low of $3.50 and a fifty-two week high of $6.85.
COPYRIGHT VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/05/co-diagnostics-codx-earning-somewhat-negative-press-coverage-study-finds.html.
Co-Diagnostics Company Profile
Co-Diagnostics, Inc is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid.
Receive News & Ratings for Co-Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.